The issuance of these patents join Calydon's collection of patents covering viral therapeutics that target and treat prostate and other cancers which includes United States Patent 5,698,443 and United States Patent 5,871,726 that cover methods for constructing a virus that incorporates the prostate-specific antigen enhancer gene
for use in specifically targeting and killing prostate cancer cells; United States Patent 5,830,686 and United States Patent 5,648,478 that claim a human prostate tissue-specific enhancer gene
and methods that utilize the prostate-specific antigen enhancer gene
for treating prostate disease; and United States Patent 5,783,435 that claims methods and compositions for screening therapeutic agents for the treatment of prostate cancer.
They include: United States Patent 5,648,478 that claims a human prostate tissue-specific enhancer gene
, and methods that utilize the PSE gene for treating prostate disease; United States Patent 5,698,443 that claims methods for constructing a virus that incorporates the human prostate tissue-specific enhancer gene
for use in targeting and treating prostate cancer cells.
Thus, the new results indicate 3 levels of Alferon LDO action which can potentially block the lethality of avian influenza: Level 1) activating dormant antiviral genes; Level 2) activating immune enhancer genes
, thereby mounting antibody attacks upon the avian influenza virus; Level 3) neutralizing the toxic by-product of the infection, TNF, thereby preventing sudden respiratory death.